Refine by MP, party, committee, province, or result type.

Results 16-30 of 106
Sorted by relevance | Sort by date: newest first / oldest first

International Trade committee  I think that the number that was published by CCPA and peer-reviewed is a credible estimate. I would like to see, as I said, the internal official estimates and, again, I think you should ask for them. I'll just point out that a lot of the savings that you've referred to, over

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I don't think the agreement provides any opportunities. I think it provides obstacles. I do agree that there are many opportunities to lower Canadian drug costs, which are about the third highest in the world. We have a very generous system of intellectual property protection fo

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  Thank you for the question. I think it should be clear from my remarks that you have to make a distinction between international trade and trade deals. Trade deals, increasingly, encroach upon matters that are only peripherally related to trade. Most of the low-hanging fruit of t

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  Again, I actually do appreciate the question. I think that if governments do not listen to constructive criticism of trade agreements, say of the type that was heard from Wallonia and their First Minister, Paul Magnette, there is a risk that you will get the demagogic criticisms

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I think it's true that it's very difficult to estimate the future costs. You should ask Joel Lexchin and Marc-André Gagnon these questions. They picked a representative sample of current drugs and estimated how many days the entry of generics would be delayed based on those two c

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I think it could have quite a serious negative impact in Canada—if it is eventually put fully into place...it won't be provisionally applied. There's still quite strong concern about it in Europe, and each member state has to ratify it. Having said that, to expand the system und

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  Thank you. The analysis that was published by CCPA, and subsequently published in a peer-reviewed journal, was by two academics, Joel Lexchin and Marc-André Gagnon. The study was done in 2013. The $850-million-per-year figure that I just cited comes from the two changes that ar

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I'm going to address the CETA today.

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  You asked why—

November 24th, 2016Committee meeting

Scott Sinclair

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  Thank you. Well, Mr. Hoback, as you're aware, there were a number of, I would say, unanticipated obstacles in Europe to the signature of CETA, which were placated through the development of a joint interpretive instrument. I don't believe your committee has studied that instrum

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I'm not convinced it's a good deal on the basis of my long study of the text, but not every Canadian has had that opportunity. Certainly only a very select number of stakeholders have been invited to participate in these particular hearings, which are quite important.

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I'm not aware of any witnesses speaking to the consumer and health implications of the patent changes. If you contrast the process to that for the trans-Pacific.... If you'd just give me an opportunity with a timeline to answer, I'll be brief. If you contrast the CETA—

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  Thank you, Mr. Eyking. Thank you for the opportunity to be part of your deliberations on whether or not Canada should ratify CETA. Today I wish to emphasize three areas where the costs of ratification for Canada outweigh the modest trade benefits. These problematic features are

November 24th, 2016Committee meeting

Scott Sinclair

International Trade committee  I was involved in the debate on NAFTA and critical of that agreement, but at the time if I'd known more about investor-state dispute settlement, I think I would have been even more opposed to it.

June 16th, 2016Committee meeting

Scott Sinclair